However, the role of simeprevir plus PegIFNα/RBV as the primary treatment for patients with HCV GT1 infection has diminished since the recent development of IFN-free DAA combinations, which provide a shorter, more effective, and better tolerated treatment across most patient populations. This evidence concerns the gene IFNA1 and infection.